resTORbio, Inc. (TORC): Product News News

TORC – Announces newly published data from a Phase 2a clinical trial demonstrating that target of rapamycin complex 1 inhibitor treatment improved immune function and decreased incidence of all infections.

Key Facts Surrounding This News Item

  • TORC had returned 0.00% year-to-date leading up to today’s news, versus a +5.40% return from the benchmark S&P 500 during the same period.

More Info About resTORbio, Inc. (TORC)

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases and conditions in the United States. It is developing TORC1 inhibitor class of pharmaceutical products, including RTB101 and RTB101 with everolimus that are in Phase IIb clinical trial for the treatment of respiratory tract infections; and that have completed Phase I clinical trials for the treatment of heart failure with preserved ejection fraction and autophagy-related neurodegenerative diseases, as well as other infections, such as urinary tract infections. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc. View our full TORC ticker page with ratings, news, and more.

TORC at a Glance

TORC Current POWR Rating™
Overall POWR Rating™
TORC Current Price $8.02 0.50%
More TORC Ratings, Data, and News

TORC Price Reaction

The day of this event (Jul. 11, 2018)
TORC Closing Price$9.30 10.98%
TORC Volume1,303,500
739.75% from avg
Leading up to this event
TORC 1-mo return17.36%
After this event
TORC 1-day return8.21%
TORC 3-day return6.37%
TORC 5-day return3.12%

TORC Price Chart

The Top Stocks For 2019

More resTORbio, Inc. (TORC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All TORC News
Page generated in 0.7331 seconds.